<DOC>
	<DOC>NCT01646736</DOC>
	<brief_summary>Evaluation the clinical efficacy and safety profile of glucocorticosteroid combined with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F) in the treatment of patients with lupus nephritis. Open-labeled, randomized, prospective multi-center clinical trial. Observation period of 24 weeks.</brief_summary>
	<brief_title>Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Age 1865 years with informed consent SLE defined by meeting 4 or more ACR classification criteria Biopsyproven active proliferative lupus glomerulonephritis ISN classification Class III or IV Active renal disease Pregnant, lactating or further fertility requirements Serum creatinine &gt; 3 mg/dL Serum ALT or AST &gt; 3 times upper limit of normal Severe, progressive renal, hepatic, hematological, gastrointestinal, pulmonary, cardiovascular, neurological, endocrine or cerebral disease Previous treated with cyclophosphamide or T2. Not discontinuing MMF, azathioprine, leflunomide, methotrexate, calcineurin inhibitor before 1 month of randomization. Active or chronic infection, including HIV, HCV, HBV, tuberculosis Patient with malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Lupus Nephritis</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Tripterygium</keyword>
</DOC>